The research company Aptahem has entered into a letter of intent for a clinical development collaboration for the company’s drug candidate Apta-1 with Professor Folke Sjöberg at Linköping University, thereby taking the next step toward patient studies. This is stated in a press release.
The parties now intend to detail the model for how the program can be carried out, with a clear division of responsibilities between drug development, clinical expertise and study planning.
